(Reuters) -Biogen said on Monday its drug for treating a rare genetic disorder has won European health regulator’s approval for use in adults and adolescents aged 16 years and older.
Biogen’s Skyclarys is the first approved drug in the European Union for Friedreich’s ataxia, a disease that causes progressive damage to the nervous system.
Biogen gained access to the drug in a $6.5 billion acquisition of Reata Pharmaceuticals, the drugmaker’s first large acquisition under CEO Christopher Viehbacher, last year.
(Reporting by Pratik Jain in Bengaluru; Editing by Shinjini Ganguli)
